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Extracellular glutamate of glial origin modulates glial and neuronal glutamate release and
synaptic plasticity. Estimates of the tonic basal concentration of extracellular glutamate
range over three orders ofmagnitude (0.02–20μM) depending on the technology employed
to make the measurement. Based upon binding constants for glutamate receptors and
transporters, this range of concentrations translates into distinct physiological and patho-
physiological roles for extracellular glutamate. Here we speculate that the difference in
glutamatemeasurements can be explained if there is patternedmembrane surface expres-
sion of glutamate release and transporter sites creating extracellular subcompartments that
vary in glutamate concentration and are preferentially sampled by different technologies.
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The concentration of glutamate varies dramatically depending
upon the biological compartment being measured. For example,
plasma glutamate levels are estimated in the range of 150μM,
cerebrospinal ﬂuid levels around 10μM, and intracellular glu-
tamate concentrations in the brain are approximately 10mM
(Danbolt, 2001; Featherstone and Shippy, 2008). The concentra-
tion of glutamate in the synaptic cleft following action potential
mediated release exceeds 1mM for <10ms, and rapidly returns
to <20 nM between release events due high afﬁnity glutamate
uptake by neurons and glia (Dzubay and Jahr, 1999). In contrast
to the agreed upon glutamate concentrations in these biologi-
cal compartments, estimates of the tonic basal concentration of
glutamate within the extracellular space outside of the synaptic
cleft varies over three orders of magnitude, ranging from 0.02 to
30μM (Herman and Jahr, 2007; Chefer et al., 2009). The vari-
ance in estimated extracellular glutamate concentration results
from electrophysiological estimatesmade in vitro from tissue slices
(0.02–0.1μM) versus in vivo measurements using microdialysis
or voltammetry (1–30μM). Discerning the reasons behind these
discrepancies and ascertaining the correct level of extracellular
glutamate outside the synaptic cleft is critical to understand-
ing the physiology of how glutamate receptors, transporters, and
antiporters regulate synaptic and glial glutamate release. Also, the
concentration of extracellular glutamate will determine its role
in metabolic processes such as cellular redox potential and neu-
rometabolic coupling between synaptic activity, glial metabolism,
andbloodﬂow(Aoyamaet al., 2008;Magistretti, 2009).Knowledge
of how these glial and neuronal glutamatergic processes homeo-
statically regulate extracellular glutamate concentrations is central
to understanding the physiology of excitatory neuroplasticity and
its emerging role in neuropsychiatric diseases. For example, extra-
cellular levels outside the synaptic cleft in the low micromolar
range place glutamate in the range of the K d for glutamate bind-
ing to extrasynaptic metabotropic glutamate receptors (mGluR),
glutamate transporters, and extrasynaptic NMDA ionotropic
glutamate receptors, while levels in low nanomolar range would
not signiﬁcantly occupy these binding sites (Conn and Pin, 1997;
Danbolt, 2001; Herman and Jahr, 2007). Here we explore possible
reasons why the in vitro electrophysiology and in vivo experiments
deliver such disparate values. Further, we propose that both mea-
surements are correctly assessing extracellular subcompartments
that differentially contain nanomolar and micromolar extracellu-
lar glutamate, and that the concentration difference arises from the
patterned expression of release and uptake sites on the membrane
surface. Themulticompartment proposal is illustrated in Figure 1,
where we outline a working deﬁnition of extracellular glutamate
into three subcompartments, including synaptic, perisynaptic, and
nonsynaptic subcompartments.
IN VIVO (μM) VERSUS IN VITRO (NM) MEASURES OF
EXTRACELLULAR GLUTAMATE IN BRAIN
Estimates of the in vivo concentration of extracellular glutamate
using microdialysis have been made in a variety of mammalian
species and in many brain regions (Chefer et al., 2009). The most
accepted approach is the no-net-ﬂux method where increasing
concentrations of exogenous glutamate are passed through the
probe and extracellular glutamate is inferred as the point where
in vivo glutamate and exogenously applied glutamate are equal
(i.e., no-net-ﬂux of glutamate across the dialysis membrane).
These studies measure 1–30μM extracellular glutamate in dif-
ferent brain regions between different mammalian species, with
the majority of studies ﬁnding levels between 1 and 5μM (Jacob-
son et al., 1985; Lerma et al., 1986; Miele et al., 1996; Baker et al.,
2003; Galvan et al., 2003; Szumlinski et al., 2004, 2005; Melendez
et al., 2005a; Miller et al., 2008; Berglind et al., 2009). Micro-
dialysis typically provides measurements at ≥1min intervals,
with most samples obtained in the range of 10–30min intervals,
and the measurement surface area (active dialysis membrane) is
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FIGURE 1 |Tonic levels of extracellular glutamate measured in the
synaptic, perisynaptic, and nonsynaptic compartments of the
extracellular space.The levels of glutamate shown are approximated for
resting conditions (i.e., in the absence of action potential mediated synaptic
release). It is proposed that extracellular glutamate in compartmentalized
morphologically by close appositions between neuronal and glial processes
(note that the distances between glia–neuron distances are exaggerated for
illustrative purposes), and by the patterned distribution of glutamate uptake
sites and neuronal or glial release sites. This creates 2 regions of nanomolar
glutamate high in iGluR, uptake sites and either synaptic (1) or glial (2)
glutamate release sites. A second region surrounding the nanomolar region
contains low micromolar levels of glutamate that are maintained largely
from glial release and relatively lower glutamate uptake via high afﬁnity
transporters. This latter compartment is in part populated by mGluR that
receive tonic glutamate stimulation and thereby modulate synaptic (and
probably glial; D’Ascenzo et al., 2007) release and neuroplasticity.
103–104 μm2 (conventional microdialysis probes range from 150
to 250μm diameter and 500 to 2000μm length). More recently,
in vivo voltammetry using biosensors coated with glutamate oxi-
dase to enzymatically reduce glutamate have been employed to
make measurements of glutamate over 0.2–30 s intervals, and
employ a measurement surface area ranging from 30 to 250μm2
(Oldenziel et al., 2004;Rahmanet al., 2005). To estimate extracellu-
lar concentrations, voltammetry typically uses both a background
electrode to subtract non-speciﬁc oxidative currents and an exter-
nal glutamate calibration curve. Although the technology and
probe characteristics differ, the measures of extracellular gluta-
mate with biosensors are similar to microdialysis estimates in the
range of 1–30μM (Day et al., 2006; Oldenziel et al., 2007; Hascup
et al., 2008; McLamore et al., 2010).
The size of the measurement surface for either microdialysis
or biosensors obviates measuring release from single synapses.
Moreover, the >1-min measurement interval in microdialysis
studies contributes to an inability of dialysis to quantify synaptic
glutamate release. Thus, the pool of glutamate being sampled by
microdialysis under resting conditions in awake animals is not
derived from action potential mediated release, as revealed by
the fact that blocking voltage-dependent sodium channels with
tetrodotoxin (TTX) does not signiﬁcantly reduce extracellular
levels of glutamate (Moghaddam, 1993; Morari et al., 1993; Tim-
merman andWesterink,1997;Timmerman et al., 1999;Baker et al.,
2002; Del Arco et al., 2003; Chefer et al., 2009). However, during
certain behavioral tasks, TTX-sensitive increases in extracellular
glutamate are measured using microdialysis (LaLumiere and Kali-
vas, 2008; Madayag et al., 2010). Some microdialysis studies ﬁnd
that voltage-dependent calcium channel antagonists partially (15–
30%) decrease extracellular glutamate, supporting contribution
by calcium-dependent glial glutamate release (D’Ascenzo et al.,
2007). While microdialysis provides a measure of tonic extracel-
lular glutamate that is integrated over time and is largely not of
synaptic origin, glutamate biosensorsmeasure basal levels of extra-
cellular glutamate that are ∼30–50% inhibited by TTX (Hascup
et al., 2008; van der Zeyden et al., 2008). Taken together, micro-
dialysis and glutamate biosensors identify a tonic pool of 1–5μM
extracellular glutamate, the majority of which is derived from
non-synaptic sources.
The sources of non-synaptic glutamate measured in vivo
include Ca++-dependent glial release and cystine–glutamate
exchange, and the basal non-synaptic concentration of extracel-
lular glutamate results from a balance between these sources and
glutamate uptake via high afﬁnity glutamate transporters (Baker
et al., 2002;Haydon et al., 2009). The cystine–glutamate antiporter
exchanges one extracellular cystine molecule for one glutamate
molecule and is a rate-limiting step in glutathione synthesis. Glia
provide the dominant contribution to dialysis measurements of
both cystine–glutamate exchange and glutamate transporter activ-
ity (Pow, 2001; Sato et al., 2002). In some brain regions inhibiting
cystine–glutamate exchange reduces the basal extracellular con-
centrationof glutamate by>50%,and inhibiting glutamate uptake
can elevate levels ﬁvefold (Baker et al., 2002). Conﬁrming the role
of cystine–glutamate exchange mediated release versus synaptic
release in regulating the extracellular pool of glutamate mea-
sured bymicrodialysis, the rise in glutamate produced by blocking
glutamate transporters is entirely prevented by blocking cystine–
glutamate exchange while TTX has no effect (Baker et al., 2002;
Melendez et al., 2005b). Also, deleting the gene transcribing the
catalytic subunit of the cystine–glutamate exchanger (xCT) causes
∼50% reduction in extracellular glutamate measured by micro-
dialysis (Massie et al., 2011). Finally, the chronic administration of
addictive drugs such as cocaine and nicotine reduce xCT expres-
sion (Knackstedt et al., 2009), and this is reﬂected by reduced basal
extracellular glutamate (Baker et al., 2003).
In contrast to the in vivo microdialysis and biosensor estimates
of low micromolar extracellular glutamate in the hippocampus
(Oldenziel et al., 2006a; Chefer et al., 2011; De Bundel et al., 2011),
two studies using hippocampal slices ﬁnd extracellular glutamate
levels in the low nanomolar range (Cavelier and Attwell, 2005;
Herman and Jahr, 2007). The authors measured tonic NMDA
receptor (NMDAr) currents mediated by non-synaptic extracellu-
lar glutamate. These studies compared this tonic NMDAr current
to the NMDAr current induced by saturating agonist (NMDA)
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concentration, and used an NMDAr dose–response curve for
glutamate activation (Hill coefﬁcient= 1.5, EC50 = 1.8–2.3μM)
generated in cultured hippocampal neurons (Patneau and Mayer,
1990) or a dose–response curve determined in a nucleated patch
of neuronal membrane from the hippocampal slice (Herman
and Jahr, 2007). Through these measurements they conclude that
extracellular glutamate concentrations in hippocampal slices are
between 23 and 89 nM (Cavelier and Attwell, 2005; Herman and
Jahr, 2007). A low nanomolar concentration of glutamate is also
consistent with estimates based upon the capacity of glutamate
transporters to scavenge extracellular glutamate at concentrations
up to 103 below the transporter K d (1–10μM; Zerangue and
Kavanaugh, 1996; Danbolt, 2001).
METHODOLOGICAL CAVEATS FOR IN VIVO AND IN VITRO
ESTIMATES OF GLUTAMATE
Below we outline various concerns that can be raised regarding
the veracity the measures of extracellular glutamate by each tech-
nology. However, our primary thesis is that the methodological
caveats onlymarginally contribute to the three-order ofmagnitude
distinction between the in vitro and in vivo studies, and that this
difference largely reﬂects the physiology of glutamate regulation
in the extracellular space.
DAMAGE PRODUCED BY IN VIVO MICRODIALYSIS PROBES OR
BIOSENSORS
The presence of non-synaptic, glial glutamate measured by dialy-
sis and biosensors has created concern that these techniques may
be over-estimating the level of extracellular glutamate, since 1–
5μM glutamate is in the vicinity of the K d for NMDA receptors
and would desensitize a portion of these receptors. Accordingly,
damage to neuropil induced by inserting the dialysis probe or a
large diameter (>100μm) biosensormay cause non-physiological
elevations of glutamate either directly from acute damage or due
to the glial inﬁltration that occurs when the probes are in the
brain for many hours, as is typical of in vivo experiments. Acute
damage is likely not a concern because most experiments are con-
ducted hours after probe insertion, and the levels of glutamate
decline to a steady-state value by the time of measurement (van
der Zeyden et al., 2008). However, the potential for glial inﬁl-
tration and creation of an artiﬁcial extracellular compartment
where glutamate can accumulate over the course of an experiment
lasting many hours needs to be considered. Since both cystine–
glutamate exchange and glutamate transport would be expected
to accompany glial inﬁltration, creating a privileged environment
with elevated glutamate concentrations is a reasonable concern.
To some extent, this concern may be obviated by the fact that
small diameter (10μm) carbon ﬁber glutamate biosensors in the
striatum ﬁnd that tonic glutamate concentrations are higher (18–
29μM glutamate) than is typical for microdialysis or standard
(>100μm diameter) biosensors (1–5μM; Kulagina et al., 1999;
Oldenziel et al., 2006b); although, one carbon ﬁber voltammetry
study reported 2μM glutamate (Rahman et al., 2005). Interest-
ingly, the higher levels of basal glutamate measured using car-
bon ﬁber biosensors were up to 90% TTX-dependent (van der
Zeyden et al., 2008), and if one considers that the total basal
levels of glutamate measured in this carbon ﬁber voltammetry
study were 18μM, the level of TTX-insensitive glutamate remain-
ing is ∼1.8μM glutamate, which is in the range measured by
microdialysis (Oldenziel et al., 2006b).
Larger basal levels with carbon ﬁber voltammetry compared
with dialysis have also been observed in studies of extracellular
dopaminewhere voltammetrymeasures∼10-foldmoredopamine
than is measured with microdialysis. Thus, mathematical model-
ing of microdialysis in brain has interposed a trauma layer between
the neuropil and probe in an effort to understand the poten-
tial impact of damage on no-net-ﬂux microdialysis estimates of
extracellular neurotransmitters (Bungay et al., 2003; Tang et al.,
2003; Chen, 2006). The conclusion from these analyses is that
damage from a microdialysis probe produces a glial barrier sepa-
rating the probe from neuropil where active dopamine uptake and
synaptic release occurs, causing dialysis to underestimate extracel-
lular dopamine levels. Thus, akin to the dopamine measurements
the trauma layer created by microdialysis probes may constitute a
barrier to synaptically released glutamate. This possibility is con-
sistent with the analysis above that subtracting the TTX-sensitive
glutamate from carbon ﬁber voltammetry measures of glutamate
results in the 1- to 5-μM TTX-insensitive glutamate measured by
microdialysis.
In spite of data indicating that dialysis could underestimate
tonic extracellular levels of glutamate by eliminating synaptically
released glutamate, it is possible that oxidative stress associated
with a trauma layer could promote glutamate levels. For exam-
ple, oxidative stress triggers transcriptional increases in xCT to
support glutathione synthesis (Shih et al., 2003; Lewerenz et al.,
2009), and thereby increases cystine/glutamate exchange. How-
ever, oxidative stress also increases glutamate uptake, in part to
provide a source of intracellular glutamate for cystine–glutamate
exchange to more effectively scavenge cystine from the extracellu-
lar environment for glutathione synthesis (Lewerenz et al., 2006).
Also,while microglia invading an area of neuronal damage express
GLT-1, these microglia also cause a reduction in glutamate trans-
porter expression on astrocytes (Domercq et al., 2007; Nakajima
et al., 2008; Tilleux and Hermans, 2008). Given these inferen-
tial and contradictory data, conclusions on how oxidative stress
induced by in vivo probe damage to neuropil may contribute to
basal glutamate measurements remains unclear.
TECHNICAL CAVEATS WITH IN VITRO SLICE EXPERIMENTS THAT MAY
AFFECT BASAL GLUTAMATE
Three technical caveats with in vitro tissue slice physiology that
could inﬂuence the concentration of extracellular glutamate mea-
sured are worth brief consideration. First, in contrast to in vivo
experiments conducted largely in adult animals, the electrophys-
iological estimates of glutamate used P15–P19 mice or P11–P13
rats (Cavelier and Attwell, 2005; Herman and Jahr, 2007), and nei-
ther glutamate transporters nor cystine–glutamate exchange are
fully expressed at this age (Kugler and Schleyer, 2004; La Bella
et al., 2007). Also, glutamatergic tone on mGluR2/3 increases dur-
ing development, such that the mGluR2/3 antagonist LY341495
is without effect on release probability at P13–17, but tone is
demonstrable by P28–42 (Chen and Roper, 2004).
A second caveat is that the open diffusion perimeter across
the slice surfaces can cause partial depletion of extracellular
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constituents unless they are actively replaced in the incubation
medium. For example, depletion of ascorbic acid and glutathione
normally found in vivo results in signiﬁcant oxidative stress in tis-
sue slices (Rice, 1999; Brahma et al., 2000); accordingly ascorbate
is added to the buffer in most slice experiments. Interestingly, the
reduction in glutathione may be related in part to depletion of the
glutathione precursor cystine, which can directly affect extracellu-
lar glutamate levels in tissue slices via activating cystine–glutamate
exchange. For example, cystine loss and a corresponding decrease
in extracellular glutamate is indicated by the fact that restor-
ing extracellular cystine to physiological levels of 100–300 nM in
cortical or striatal slices activates cystine/glutamate exchange to
increase extracellular glutamate levelsmeasuredby slicemicrodial-
ysis, and restores tone onto mGluR2/3 release regulating autore-
ceptors (Moran et al., 2005). Contrary to this observation, when
glutamate transporters are blocked in hippocampal slices NMDAr
currents do not plateau, indicating that signiﬁcant washout of
glutamate may not be occurring (Herman and Jahr, 2007).
A ﬁnal consideration is also related to the impact of making
tissue slices on measures of synaptic transmission. A number of
changes are induced by making hippocampal tissue slices on den-
dritic spinemorphology, glial coverage of synapses and spines, and
on the intracellular structure of dendrites (Witcher et al., 2007).
For example, spine density is higher in hippocampal pyramidal
neurons in recovered tissue slices than in hippocampal tissue ﬁxed
in vivo, and the extent of difference depends on different incu-
bations conditions such as temperature and buffer constituents
(Fiala et al., 2003; Bourne and Harris, 2008). As well, synapses in
recovered hippocampal slices contain less glial coverage (Witcher
et al., 2007).While all of these factors could affect the extracellular
levels of glutamate in tissue slices, it remains to be determined
how inﬂuential they are on synaptic physiology and extracellular
glutamate levels.
CAN EXTRACELLULAR SUBCOMPARTMENTS EXPLAIN THE
IN VITRO ESTIMATE OF TONIC GLUTAMATE AND THE μM
LEVELS MEASURED IN VIVO?
One explanation for the difference between the in vivo and in vitro
measures of glutamatemay lie in thepresenceof subcompartments
of extracellular glutamate. The synaptic cleft is one subcompart-
ment where glutamate levels are tightly regulated by both synaptic
and glial glutamate uptake, and the concentration of glutamate is
in the low nanomolar range to prevent desensitization of iGluR.
The standing NMDAr current used to estimate extracellular glu-
tamate levels in vitro are located in both the synaptic cleft and
extrasynaptic membrane, with extrasynaptic NMDAr constitut-
ing ∼36% of total NMDAr in P14–21 acute hippocampal slices
(Harris and Pettit, 2007); the age of animals used to estimate glu-
tamate levels fromNMDAr currents in slice studies (see discussion
above). Electronmicroscopy reveals that akin to synaptic NMDAr,
approximately 80% of the extrasynaptic NMDAr are localized
to points of near contact between adjacent processes (Harding-
ham and Bading, 2010; Petralia et al., 2010). This is similar to
estimates for the proportion of glutamate transporters also clus-
tered adjacent to the synaptic cleft and at points of near contact
by neuron–glial processes (Chaudhry et al., 1995; Cholet et al.,
2002). Although never experimentally tested, if one assumes that
the patterned expression of NMDAr and glutamate transporters
is fairly widespread in the brain and not just the hippocampus
or cerebellum (Bourne and Harris, 2008), the NMDAr may con-
tact lower concentrations of tonic extracellular glutamate due to
being localized in the vicinity of glutamate transporters. If indeed
NMDAr both inside and outside the synaptic cleft are localized to
areas of relatively high glutamate uptake, and thereby in regions
of low basal glutamate tone, the electrophysiological estimates of
extracellular glutamate made using whole cell patch measures of
standingNMDAr currentswould reﬂect extracellular subcompart-
ment(s) that contain nanomolar glutamate. In contrast, outside
these areas of relatively high glutamate uptake and NMDAr, gluta-
mate would have a tendency to accumulate. The localization of the
majority of NMDAr to such specialized compartments also offers
an explanation for the observation that in contrast to applying
NMDA, glutamate application to tissue slices in concentrations
akin to those measured in vivo (2μM) does not readily activate
NMDAr (Herman and Jahr, 2007). Thus, a high density of glu-
tamate transporters in the vicinity of the synapse would protect
synaptic NMDAr from both endogenous non-synaptic glutamate
released from glia and experimenter delivered non-synaptic gluta-
mate. Together these data are consistent with a perspective that the
standing NMDAr current created by endogenous tonic glutamate
is in the low nanomolar range because themajority of NMDAr are
localized to extracellular compartments where glutamate trans-
porters are also enriched and basal glutamate levels are low (i.e., in
the synapse and extrasynaptic specializations with high capacity
for glutamate uptake).
The possible compartmentalization of different concentrations
of extracellular glutamate is buttressed by measuring glutamater-
gic tone onmGluRs that are largely localized to extrasynaptic sites,
and may therefore be exposed to higher basal levels of glutamate
(Whittington et al., 1995; Schrader and Tasker, 1997; Marek et al.,
2000; Oliet et al., 2001; Losonczy et al., 2003; Acuna-Goycolea
et al., 2004; Wang et al., 2005; Ren et al., 2007). Although not
intended to quantify extracellular glutamate concentrations in
tissue slices, by considering EC50s of glutamate at mGluR and
mGluR antagonist dose–response curves, these studies indicate
extracellular glutamatergic tone onmGluRs in the lowmicromolar
range. For example, in hippocampal slices the mGluR2/3 selective
antagonist LY341495 potentiates the amplitude of evoked EPSCs
by 36%, and a 15.5% potentiation of spontaneous EPSC (sEPSC)
frequency was produced by the group IIImGluR (4/6/7/8) antago-
nistCPPG inhypothalamic orexinneurons (Acuna-Goycolea et al.,
2004). Equivalent ﬁndings exist from studies using mGluR2/3 or
mGluR4/6/7/8 antagonists in the medial PFC, substantia nigra,
and supraoptic nucleus (Marek et al., 2000; Oliet et al., 2001;
Wang et al., 2005). Since mGluR2/3 and mGluR4/5/6/7 are largely
extrasynaptic and have an EC50 for glutamate in the range of 1–
10μM (Tanabe et al., 1992; Conn and Pin, 1997; Pin et al., 1999),
these results suggest that extracellular, extrasynaptic glutamate in
brain slices is in the low micromolar range. Finally, studies mea-
suring presynaptic AMPA/kainite ionotropic receptors [glutamate
EC50 = 10.2μM (Li et al., 1995)] indicate low micromolar gluta-
mate tone since the AMPA antagonist NBQX reduces glutamate
release by 36% (Ren et al., 2007). Finally, in vivo studies using local
application of mGluR2/3 antagonist reveal glutamatergic tone
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on mGluR2/3s regulating the size of excitatory ﬁeld potentials.
By passing increasing concentrations of an mGluR2/3 antagonist
through a dialysis probe adjacent to a recording electrode in the
nucleus accumbens, itwas shown that the amplitudeof ﬁeldpoten-
tials elicited by stimulating prefrontal glutamatergic afferents to
the accumbens were under tonic inhibition by glutamate activa-
tion of mGluR2/3 (Moussawi et al., 2011).While these in vitro and
in vivo data are consistent with glutamate tone on mGluRs, it is
possible that constitutive activity of themGluRs could account for
some of the observed tone.
In summary, the use of standing NMDAr currents to estimate
tonic extracellular glutamatemay reﬂect glutamate concentrations
in subcompartments of the extracellular space that are particularly
dense in both NMDAr and glutamate transporters. Accordingly,
this measure may not represent levels of glutamate that can accu-
mulate in extracellular compartments where relatively less gluta-
mate uptake and tonic glial release may create levels closer to the
1- to 10-μMmeasured by biosensors ormicrodialysis. Thus,when
extrasynaptic effects of glutamate aremeasured atmGluRorpresy-
naptic iGluR, the electrophysiological data are largely consistent
with in vivo estimates of extracellular glutamate in the low micro-
molar range. A resolution to the marked differences in estimated
concentrations of extracellular glutamate is depicted in Figure 1.
Thus, at least two compartments of extracellular glutamate could
exist; one compartment high in iGluR and glutamate transport
and release processes (e.g., the synapse and perhaps non-synaptic
neuron–neuron and neuron–glia appositions) that contains low
nanomolar glutamate. Another non-synaptic compartment con-
taining low micromolar glutamate and mGluRs is maintained
largely by glial release and maintains a relatively lower density
of glutamate transporters.
SUBCOMPARTMENTS OF EXTRACELLULAR GLUTAMATE
DIFFERENTIALLY REGULATE EXCITATORY TRANSMISSION
AND PLASTICITY
A computational model recently suggested that extracellular glu-
tamate exists at different concentrations in distinctly regulated but
continuous subcompartments, termed synaptic, perisynaptic, and
nonsynaptic (Pendyamet al.,2009). Thismodel accommodates the
discrepancy between in vitro electrophysiological estimates of glu-
tamate based on NMDAr currents (synaptic), the in vitro electro-
physiological estimates based on mGluR pharmacology (perisy-
naptic), and the dialysis/biosensor in vivo studies that directly
measure glutamate levels (nonsynaptic). Thus, the synaptic com-
partment contains low nanomolar glutamate that is regulated by
synaptic release and neuronal/glial glutamate transporters, while
the nonsynaptic space contains low micromolar glutamate that
is regulated by glial glutamate release and glial transporters, and
the perisynaptic compartment containing mGluRs was modeled
as a transition zone inﬂuenced by both tonic glial glutamate
release and synaptic glutamate release (Figure 1; Pendyam et al.,
2009).
An important aspect of this model is the patterned membrane
surface expression of glutamate transporters and glial release sites
that creates the equivalent of a semipermeable barrier between the
synaptic and non-synaptic extracellular environments. The high
afﬁnity Na+-dependent glutamate transporter family includes ﬁve
subtypes known as excitatory amino acid transporters (EAAT1–
5; Danbolt, 2001). EAAT1 (GLAST) and EAAT2 (GLT-1) are
expressed mainly in astrocytes, and EAAT3 and EAAT4 in neu-
rons, whereas EAAT5 expression is limited to retina (Danbolt,
2001). GLAST and GLT-1 are non-uniformly expressed on glial
membranes, with 73% of labeled transporters ensheathing excita-
tory synapses, dendritic spines, and other neuronal process contact
sites (Cholet et al., 2002). Similarly, high expression of neuronal
EAAT4 in the synaptic compartment strongly regulates the access
of synaptic glutamate to mGluRs in the perisynaptic environment
(Wadiche and Jahr, 2005). In addition to the patterned expres-
sion of transporters, the activity of transporters is non-linear in
their contribution to reducing extracellular glutamate (Herman
and Jahr, 2007), posing the possibility that different afﬁnity trans-
porters may be selectively localized to maintain different levels of
extracellular glutamate. An additional subtlety arising from glia–
neuronmorphological specializations and patterned expression of
glutamate transporters is that synaptic glutamatemay have greater
access to the perisynaptic environment at the pre-synapse than at
the post-synapse, indicating greater inﬂuence on release regulat-
ing mGluRs (Lehre and Rusakov, 2002). It is also noteworthy that
non-synaptic neuronal release may occur in synapse-like extra-
cellular compartments that maintain nanomolar concentrations
of glutamate. Thus, the rapid/transient stimulation of AMPAr on
cerebellar Bergman glial cells by neuronal glutamate arises from a
non-synaptic specialization containing high glial AMPAr density
and rapid glutamate elimination (Matsui and Jahr, 2004; Matsui
et al., 2005).
In contrast to neuronal release in the synaptic compartment,
both in vitro electrophysiological and in vivo dialysis/biosensor
studies indicate the presence of tonic extracellular glutamate
derived from glia (Cavelier and Attwell, 2005; Chefer et al., 2009).
Three sources of glutamate release from glia into the extrasynap-
tic space under physiological conditions have obtained signiﬁ-
cant experimental evidence, including Ca++-dependent (Halassa
and Haydon, 2010), cystine–glutamate exchange (Baker et al.,
2002), and passive diffusion (perhaps regulated by pH; Cave-
lier and Attwell, 2005). As with disparities in the concentration
of extracellular glutamate, which glial source of glutamate con-
tributes to the extracellular environment depends on the method
of measurement. While in vitro electrophysiological studies using
NMDAr currents to estimate the source of tonic glutamate in
brain slices ﬁnd no inﬂuence by Ca++-dependent or cystine–
glutamate exchange (Jabaudon et al., 1999; Cavelier and Attwell,
2005), microdialysis/biosensors ﬁnd contributions by both of
these mechanisms (Baker et al., 2002; Halassa and Haydon, 2010).
Conversely, NMDAr current estimates of tonic extracellular gluta-
mate identiﬁed only passive glutamate release, perhaps regulated
by pH (Cavelier and Attwell, 2005), indicating an estimate reﬂect-
ing levels of glutamate in an extracellular compartment that largely
excludes glutamatederived fromCa++-dependent glial release and
cystine–glutamate exchange, such as the synaptic cleft (Figure 1).
As with synaptic release, the accumulation of extracellular
glutamate derived from glial release is regulated by glutamate
transporters (Melendez et al., 2005b); although the density of
transporters is lower, thereby permitting extracellular glutamate
to accumulate into a low micromolar range. While patterned
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expression of glutamate transporters relative to the location of
glial Ca++-dependent release sites or cystine–glutamate exchang-
ers has not been studied, it is noteworthy that the preferred source
of intracellular glutamate released by cystine–glutamate exchange
is glutamate recently taken-up by GLT-1, implying physical prox-
imity of GLT-1 and cystine–glutamate exchange (Lewerenz et al.,
2006), and the surface expression of GLT-1 and xCT may be co-
regulated (Knackstedt et al., 2010). Thus, akin to the synaptic
cleft where patterned expression of glutamate transport adjacent
to the cleft tightly regulates tonic glutamate at low nanomolar
levels, co-expression and regulation of glutamate transport and
cystine–glutamate exchange may also regulate tonic micromolar
extracellular glutamate.
Finally it is important to caveat the model illustrated in
Figure 1. First,most research characterizing patterned transporter
localization and glial apposition to excitatory synapses has been
conducted at hippocampal, and to a lesser extent cerebellar and
cortical excitatory synapses (Diamond and Jahr, 2000; Bourne and
Harris, 2008). Thus, it remains unknown towhat extent thesemor-
phological and attending physiological implications apply outside
these areas. Second, even in the hippocampus serial electron
microscopy and three-dimensional reconstruction shows that only
∼60%of the synapses have adjacent glial projections (Ventura and
Harris, 1999; Witcher et al., 2007). While it has been speculated
that these synapses may be the most active synapses based on hav-
ing larger synapse diameters (Witcher et al., 2007), this poses the
possibility that not all excitatory synapses in the brain contain the
conﬁguration illustrated in Figure 1, and that some synaptic glu-
tamate will have access to extrasynaptic space, and perhaps even to
adjacent synapses (see Rusakov and Kullmann, 1998; Bergles et al.,
1999; Witcher et al., 2007 for detailed discussion of these issues).
CONCLUSION
The disparate estimates of the concentration and glial sources
of tonic extracellular glutamate depend upon the technologies
applied and the possibility that the different approaches may
be measuring distinct extracellular compartments (Table 1 for
summary). Thus, low nanomolar estimates of tonic glutamate
are made in vitro using NMDAr currents, while low micromo-
lar estimates are derived both in vivo or in vitro using micro-
dialysis or glutamate biosensors. The latter direct measures of
glutamate also identify Ca++-dependent release and cystine–
glutamate exchange as the important sources of glial glutamate
release, while using NMDAr currents eliminates these sources
and ﬁnds only passive diffusion to provide tonic non-synaptic
glutamate. Based upon glutamate transporters being in highest
density adjacent to the synaptic cleft, and perhaps at non-synaptic
contacts containing NMDAr (Figure 1), we propose that tonic
NMDAr currents are estimating glutamate largely at points of
cellular contact where glutamate values are in the low nanomo-
lar range and contributions from Ca++-dependent glial release
and cystine–glutamate exchange are largely absent. Conversely,
direct measurement of glutamate in vivo identiﬁes micromolar
concentrations of glutamate that exist outside of the synaptic
environment, are derived in part from glial Ca++-dependent
mechanisms and cystine–glutamate exchange, and provide tone
onto perisynaptic mGluR. In this way, the inﬂuence of synaptic
glutamate release is largely limited in space to the synaptic and
Table 1 | Characteristics of tonic extracellular glutamate measured
using different technologies.
Characteristic Patch
electrophysiology
Carbon fiber
voltammetry
Microdialysis
Measurement NMDAr current Glutamate Glutamate
Time interval ms s min
Glutamate
(μM)
0.02–0.1 2–20 1–5
Probe size
(μm)
1 10 200×1000
Trauma layer1 No No Yes
mGluR tone2 Yes ? Yes
Source of
tonic Glu3
Glia 50–70% glia Glia
Glial sources
of tonic Glu
Passive diffusion; pH ? Ca++-
dependent;
Cys/Glu
exchange
1Trauma layer refers to measurements made inside of damaged neuropil. Thus,
while the preparation of a slice for patch electrophysiology induces damage, actual
measurements are made from intact neuropil, usually 20–50μm from the slice
surface.
2mGluR tone is estimated by mGluR antagonists alleviating tonic modulation by
extracellular glutamate.
3Glutamate of glial origin in the extracellular space is estimated using patch elec-
trophysiology to measure NMDAr standing current amplitude after blocking action
potentials withTTX, and pharmacologically inhibiting AMPA and GABA ionotropic
currents. For in vivo measures, the proportion of glial glutamate is estimated by
blocking neuronal release withTTX. For example,TTX does not reduce glutamate
measured by microdialysis.
immediate perisynaptic environment, thereby providing tempo-
rally coded excitatory neuronal communication in themsec range.
In contrast, glutamate of glial origin in the non-synaptic extracel-
lular compartment provides tonic inﬂuence on synaptic release
and postsynaptic responsiveness through pre- and postsynaptic
mGluR. The role of mGluR stimulation in regulating synaptic
plasticity is well-characterized and permits glial release to con-
tribute to the long-term regulation of synaptic strength (Losonczy
et al., 2003; Gladding et al., 2009). Importantly, neuropsychi-
atric diseases have been linked to neuropathologies in mGluRs
and glial glutamate release and uptake that in turn alter how
mGluRs regulate the potentiation and depotentiation of excitatory
transmission (Coyle, 2006; Luscher and Huber, 2009; Moussawi
et al., 2009; Yang et al., 2009). Thus, clear understanding of the
physiological concentrations and regulation of synaptic and non-
synaptic glutamate and how these two compartments of extra-
cellular glutamate interact is necessary to assess the signiﬁcance of
disease-associated changes in proteins regulating glutamate recep-
tors and glutamate release and uptakemechanisms.Unfortunately,
experiments to directly evaluate the possibility of the extracellular
subcompartments outlined in Figure 1 remain to be conducted.
Such future studies include quantitative morphological measure-
ments to determine how pervasive clustering of relevant proteins
is at points of glia–neuron apposition (e.g., NMDAr, glutamate
transporters, cystine–glutamate antiporter). Also, simultaneous
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measurementswith carbonﬁber voltammetry andwhole cell patch
measurements in tissue slices would reveal if both compartments
can be simultaneously measured.
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